The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online November 10, 2008
doi:10.1084/jem.20081398
The Journal of Experimental Medicine, Vol. 205, No. 12, 2763-2779
The Rockefeller University Press, 0022-1007 $30.00
© 2008 Jones et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 10720K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, R. B.
Right arrow Articles by Ostrowski, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. B.
Right arrow Articles by Ostrowski, M. A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

R. Brad Jones1, Lishomwa C. Ndhlovu5, Jason D. Barbour6, Prameet M. Sheth2, Aashish R. Jha5, Brian R. Long5, Jessica C. Wong1, Malathy Satkunarajah3, Marc Schweneker5, Joan M. Chapman5, Gabor Gyenes1, Bahareh Vali2, Martin D. Hyrcza2, Feng Yun Yue1, Colin Kovacs4, Aref Sassi8, Mona Loutfy7, Roberta Halpenny7, Desmond Persad8, Gerald Spotts6, Frederick M. Hecht6, Tae-Wook Chun9, Joseph M. McCune5, Rupert Kaul2, James M. Rini3, Douglas F. Nixon5, and Mario A. Ostrowski1,2,10

1 Department of Immunology, 2 Clinical Sciences Division, 3 Department of Biochemistry, and 4 Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada
5 Division of Experimental Medicine and 6 HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94110
7 Canadian Immunodeficiency Research Collaborative, 8 Maple Leaf Medical Clinic, Toronto, ON M5B 1L6, Canada
9 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
10 Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON M5B 1W8, Canada

CORRESPONDENCE Brad Jones: brad.jones{at}utoronto.ca; OR Mario Ostrowski: mario.ostrowski{at}gmail.com

Progressive loss of T cell functionality is a hallmark of chronic infection with human immunodeficiency virus 1 (HIV-1). We have identified a novel population of dysfunctional T cells marked by surface expression of the glycoprotein Tim-3. The frequency of this population was increased in HIV-1–infected individuals to a mean of 49.4 ± SD 12.9% of CD8+ T cells expressing Tim-3 in HIV-1–infected chronic progressors versus 28.5 ± 6.8% in HIV-1–uninfected individuals. Levels of Tim-3 expression on T cells from HIV-1–infected inviduals correlated positively with HIV-1 viral load and CD38 expression and inversely with CD4+ T cell count. In progressive HIV-1 infection, Tim-3 expression was up-regulated on HIV-1–specific CD8+ T cells. Tim-3–expressing T cells failed to produce cytokine or proliferate in response to antigen and exhibited impaired Stat5, Erk1/2, and p38 signaling. Blocking the Tim-3 signaling pathway restored proliferation and enhanced cytokine production in HIV-1–specific T cells. Thus, Tim-3 represents a novel target for the therapeutic reversal of HIV-1–associated T cell dysfunction.


Abbreviations used: bDNA, branched-chain DNA; CEF, CMV/EBV/Influenza; CIRC, Canadian Immunodeficiency Research Collaborative; HAART, highly active antiretroviral therapy; MFI, mean fluorescence intensity; mRNA, messenger RNA; P+I, PMA/Ionomycin; SEB, staphylococcus enterotoxin B; sTIM-3, soluble TIM-3.

R.B. Jones and L.C. Ndhlovu contributed equally to this paper.

© 2008 Jones et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS